Literature DB >> 31469438

The pipeline of antiviral T-cell therapy: what's in the clinic and undergoing development.

Alyssa Fatic1, Nan Zhang1, Michael D Keller1,2,3, Patrick J Hanley1,3,4.   

Abstract

Virus-specific T cells allow targeting of multiple pathogens in patients after hematopoietic stem cell transplantation and have demonstrated potential efficacy for cytomegalovirus, Epstein-Barr Virus, and adenovirus. Novel targets may include BK virus, JC virus, varicella zoster virus, human herpesvirus 6, Aspergillus, human parainfluenza virus-3, herpes simplex virus Type I, Zika virus, and mycobacteria. Generation of patient-specific products and third-party products may expand feasibility of therapy.
© 2019 AABB.

Entities:  

Mesh：

Year:  2019        PMID： 31469438      PMCID： PMC9359816          DOI： 10.1111/trf.15501

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.337


  14 in total

1.  Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.

Authors:  Katia Perruccio; Antonella Tosti; Emanuela Burchielli; Fabiana Topini; Loredana Ruggeri; Alessandra Carotti; Marusca Capanni; Elena Urbani; Antonella Mancusi; Franco Aversa; Massimo F Martelli; Luigina Romani; Andrea Velardi
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

2.  The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.

Authors:  Joshua A Hill; Bryan T Mayer; Hu Xie; Wendy M Leisenring; Meei-Li Huang; Terry Stevens-Ayers; Filippo Milano; Colleen Delaney; Mohamed L Sorror; Brenda M Sandmaier; Garrett Nichols; Danielle M Zerr; Keith R Jerome; Joshua T Schiffer; Michael Boeckh
Journal:  Blood       Date:  2017-02-16       Impact factor: 22.113

Review 3.  Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders.

Authors:  Katherine M Harris; Blachy J Davila; Catherine M Bollard; Michael D Keller
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-21

4.  Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy.

Authors:  Chun K K Ma; Leighton Clancy; Shivashni Deo; Emily Blyth; Kenneth P Micklethwaite; David J Gottlieb
Journal:  Cytotherapy       Date:  2016-10-25       Impact factor: 5.414

5.  CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.

Authors:  Patrick J Hanley; Jan J Melenhorst; Sarah Nikiforow; Phillip Scheinberg; James W Blaney; Gail Demmler-Harrison; C Russell Cruz; Sharon Lam; Robert A Krance; Kathryn S Leung; Caridad A Martinez; Hao Liu; Daniel C Douek; Helen E Heslop; Cliona M Rooney; Elizabeth J Shpall; A John Barrett; John R Rodgers; Catherine M Bollard
Journal:  Sci Transl Med       Date:  2015-04-29       Impact factor: 17.956

6.  Generation of Zika virus-specific T cells from seropositive and virus-naïve donors for potential use as an autologous or "off-the-shelf" immunotherapeutic.

Authors:  Ryo Hanajiri; Gelina M Sani; Patrick J Hanley; Cassia G Silveira; Esper G Kallas; Michael D Keller; Catherine M Bollard
Journal:  Cytotherapy       Date:  2019-07-04       Impact factor: 5.414

7.  Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.

Authors:  Lauren P McLaughlin; Haili Lang; Elizabeth Williams; Kaylor E Wright; Allison Powell; Conrad R Cruz; Anamaris M Colberg-Poley; Cecilia Barese; Patrick J Hanley; Catherine M Bollard; Michael D Keller
Journal:  Cytotherapy       Date:  2016-09-28       Impact factor: 5.414

8.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Authors:  Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

9.  Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy.

Authors:  Muharrem Muftuoglu; Amanda Olson; David Marin; Sairah Ahmed; Victor Mulanovich; Sudhakar Tummala; T Linda Chi; Alessandra Ferrajoli; Indreshpal Kaur; Li Li; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  N Engl J Med       Date:  2018-10-11       Impact factor: 91.245

10.  Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

Authors:  Ifigeneia Tzannou; Anastasia Papadopoulou; Swati Naik; Kathryn Leung; Caridad A Martinez; Carlos A Ramos; George Carrum; Ghadir Sasa; Premal Lulla; Ayumi Watanabe; Manik Kuvalekar; Adrian P Gee; Meng-Fen Wu; Hao Liu; Bambi J Grilley; Robert A Krance; Stephen Gottschalk; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen; Bilal Omer
Journal:  J Clin Oncol       Date:  2017-08-07       Impact factor: 44.544
View more
  3 in total

Review 1.  Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation.

Authors:  Ajit P Limaye; Tara M Babu; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2020-10-28       Impact factor: 26.132

Review 2.  Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies.

Authors:  Maria Cancio; Rachele Ciccocioppo; Patricia R M Rocco; Bruce L Levine; Vincenzo Bronte; Catherine M Bollard; Daniel Weiss; Jaap Jan Boelens; Patrick J Hanley
Journal:  Cytotherapy       Date:  2020-05-07       Impact factor: 5.414

Review 3.  Antiviral Agents as Therapeutic Strategies Against Cytomegalovirus Infections.

Authors:  Shiu-Jau Chen; Shao-Cheng Wang; Yuan-Chuan Chen
Journal:  Viruses       Date:  2019-12-23       Impact factor: 5.048
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.